Sugi Predict

Sugi Predict / Targets / IPO9

IPO9

Importin-9 · Q96P70 · IPO9 on Sugi Atlas →

0 patent compounds predicted against IPO9, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to IPO9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection PHASE3COMPLETED
Ivermectin and Nitazoxanide Combination Therapy for COVID-19 PHASE2/PHASE3UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Efficacy of Ivermectin in COVID-19 PHASE1/PHASE2COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study nanUNKNOWN
Chromosome 9 P Minus Syndrome nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic nanCOMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI) nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage nanUNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases nanUNKNOWN
Family Study of Melanoma in Italy nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IPO9 binder may also engage these)

ProteinNameSimilarity
Q91YE6 — 1.000 Q91YE6 →
Q924C1 — 0.990 Q924C1 →
O59809 — 0.989 O59809 →
O60518 — 0.989 O60518 →
Q8BKC5 — 0.988 Q8BKC5 →
Q8BIV3 — 0.988 Q8BIV3 →
A5WW24 — 0.987 A5WW24 →
O60100 — 0.986 O60100 →
Q7PC79 — 0.986 Q7PC79 →
XPO5 Exportin-5 0.986 landscape →
Q0P5A6 — 0.985 Q0P5A6 →
Q9VGP4 — 0.985 Q9VGP4 →
Q5ZMR9 — 0.985 Q5ZMR9 →
Q9QZE5 — 0.985 Q9QZE5 →
IPO5 Importin-5 0.985 landscape →
PSMD5 26S proteasome non-ATPase regulatory subunit 5 0.985 landscape →
Q6GMY9 — 0.984 Q6GMY9 →
Q5IFJ8 — 0.984 Q5IFJ8 →
Q9ESJ0 — 0.984 Q9ESJ0 →
Q7TMY7 — 0.984 Q7TMY7 →
Q9I8E6 — 0.984 Q9I8E6 →
COPG1 Coatomer subunit gamma-1 0.984 landscape →
CSE1L Exportin-2 0.984 landscape →
Q499Y0 — 0.984 Q499Y0 →
Q9QXK3 — 0.984 Q9QXK3 →
TBCD Tubulin-specific chaperone D 0.983 landscape →
Q2U3V3 — 0.983 Q2U3V3 →
Q8K2V6 — 0.983 Q8K2V6 →
A1DEK2 — 0.983 A1DEK2 →
Q802D3 — 0.983 Q802D3 →